Avidity Biosciences (RNA) Competitors $13.09 0.00 (0.00%) As of 05/22/2026 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIWShould you buy Avidity Biosciences stock or one of its competitors? MarketBeat compares Avidity Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avidity Biosciences include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry. RNA vs. AIMDWRNA vs. ALVOWRNA vs. ARAVRNA vs. ACABWRNA vs. BFRIWHow does Avidity Biosciences compare to Ainos?Avidity Biosciences (NASDAQ:RNA) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Is RNA or AIMDW more profitable? Ainos has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Ainos' return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-3,650.39% -44.92% -39.57% Ainos N/A N/A N/A Does the media favor RNA or AIMDW? In the previous week, Avidity Biosciences' average media sentiment score of 0.00 equaled Ainos'average media sentiment score. Company Overall Sentiment Avidity Biosciences Neutral Ainos Neutral Which has better valuation & earnings, RNA or AIMDW? Ainos has lower revenue, but higher earnings than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$36.68M6.10-$322.30MN/AN/AAinos$18.11KN/AN/AN/AN/A Do analysts rate RNA or AIMDW? Avidity Biosciences currently has a consensus price target of $69.42, indicating a potential upside of 430.34%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avidity Biosciences is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAvidity Biosciences beats Ainos on 5 of the 8 factors compared between the two stocks.How does Avidity Biosciences compare to Alvotech?Alvotech (NASDAQ:ALVOW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Does the media refer more to ALVOW or RNA? In the previous week, Alvotech's average media sentiment score of 0.00 equaled Avidity Biosciences'average media sentiment score. Company Overall Sentiment Alvotech Neutral Avidity Biosciences Neutral Do analysts prefer ALVOW or RNA? Avidity Biosciences has a consensus price target of $69.42, suggesting a potential upside of 430.34%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37 Which has higher earnings and valuation, ALVOW or RNA? Alvotech has higher revenue and earnings than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$586.32MN/AN/AN/AN/AAvidity Biosciences$36.68M6.10-$322.30MN/AN/A Is ALVOW or RNA more profitable? Alvotech has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Alvotech's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AlvotechN/A N/A N/A Avidity Biosciences -3,650.39%-44.92%-39.57% SummaryAlvotech and Avidity Biosciences tied by winning 4 of the 8 factors compared between the two stocks.How does Avidity Biosciences compare to Aravive?Avidity Biosciences (NASDAQ:RNA) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Which has better valuation & earnings, RNA or ARAV? Aravive has lower revenue, but higher earnings than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$36.68M6.10-$322.30MN/AN/AAraviveN/AN/AN/A-$0.90N/A Do insiders and institutionals have more ownership in RNA or ARAV? 35.8% of Aravive shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer RNA or ARAV? In the previous week, Avidity Biosciences' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score. Company Overall Sentiment Avidity Biosciences Neutral Aravive Neutral Is RNA or ARAV more profitable? Aravive has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Aravive's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-3,650.39% -44.92% -39.57% Aravive N/A N/A N/A Do analysts recommend RNA or ARAV? Avidity Biosciences currently has a consensus target price of $69.42, indicating a potential upside of 430.34%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Avidity Biosciences is more favorable than Aravive.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAravive beats Avidity Biosciences on 6 of the 11 factors compared between the two stocks.How does Avidity Biosciences compare to Atlantic Coastal Acquisition Corp. II?Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Avidity Biosciences (NASDAQ:RNA) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations. Do analysts rate ACABW or RNA? Avidity Biosciences has a consensus price target of $69.42, indicating a potential upside of 430.34%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Atlantic Coastal Acquisition Corp. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atlantic Coastal Acquisition Corp. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37 Which has better earnings & valuation, ACABW or RNA? Atlantic Coastal Acquisition Corp. II has higher earnings, but lower revenue than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AAvidity Biosciences$36.68M6.10-$322.30MN/AN/A Does the media favor ACABW or RNA? In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Avidity Biosciences'average media sentiment score. Company Overall Sentiment Atlantic Coastal Acquisition Corp. II Neutral Avidity Biosciences Neutral Is ACABW or RNA more profitable? Atlantic Coastal Acquisition Corp. II has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Atlantic Coastal Acquisition Corp. II's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Atlantic Coastal Acquisition Corp. IIN/A N/A N/A Avidity Biosciences -3,650.39%-44.92%-39.57% SummaryAvidity Biosciences beats Atlantic Coastal Acquisition Corp. II on 5 of the 8 factors compared between the two stocks.How does Avidity Biosciences compare to Biofrontera?Avidity Biosciences (NASDAQ:RNA) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends. Do analysts rate RNA or BFRIW? Avidity Biosciences presently has a consensus target price of $69.42, suggesting a potential upside of 430.34%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avidity Biosciences is more favorable than Biofrontera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37Biofrontera 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor RNA or BFRIW? In the previous week, Biofrontera had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score. Company Overall Sentiment Avidity Biosciences Neutral Biofrontera Neutral Which has stronger valuation and earnings, RNA or BFRIW? Biofrontera has higher revenue and earnings than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$36.68M6.10-$322.30MN/AN/ABiofrontera$43.20MN/AN/AN/AN/A Is RNA or BFRIW more profitable? Biofrontera has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Biofrontera's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-3,650.39% -44.92% -39.57% Biofrontera N/A N/A N/A SummaryBiofrontera beats Avidity Biosciences on 5 of the 9 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition ExportMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.92M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-2.6318.7421.2225.65Price / Sales6.10323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book1.207.0910.377.14Net Income-$322.30M$24.45M$3.57B$335.98M7 Day Performance1.08%5.45%6.01%3.56%1 Month Performance-2.97%2.43%3.52%2.54%1 Year Performance-57.19%62.98%34.13%35.05% Avidity Biosciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences1.7791 of 5 stars$13.09flat$69.42+430.3%-57.2%$223.92M$36.68MN/A190Analyst DowngradeAIMDWAinosN/A$0.07+13.2%N/A-71.2%$0.00$18.11KN/A40Positive NewsGap UpALVOWAlvotechN/A$0.24+19.0%N/A-89.5%$0.00$586.32MN/A4Positive NewsGap UpARAVAraviveN/A$0.04flatN/AN/A$0.00N/AN/A20High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.00flatN/A-77.3%$0.00N/AN/A15 Related Companies and Tools Related Companies Ainos Competitors Alvotech Competitors Aravive Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors Celularity Competitors Cingulate Competitors Comera Life Sciences Competitors Dermata Therapeutics Competitors enGene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
